Heplisav-B Vaccine Bests Standard 3-Dose Series in Heart, Lung Transplant Candidates

Findings from a recent study suggest Heplisav-B should be the preferred hepatitis B virus (HBV) vaccine in the pretransplant setting for thoracic organ transplant candidates, highlighting superior compliance and higher seroprotection rates than the conventional 3-dose series.